Trials / Completed
CompletedNCT01324492
Safety and Efficacy of RAD001 in Chinese Patients With Advanced Pulmonary Neuroendocrine Tumor
A Phase Ib, Open-label Study to Evaluate RAD001 as Monotherapy Treatment in Chinese Patients With Advanced Pulmonary Neuroendocrine Tumor
- Status
- Completed
- Phase
- Phase 1
- Study type
- Interventional
- Enrollment
- 16 (actual)
- Sponsor
- Novartis Pharmaceuticals · Industry
- Sex
- All
- Age
- 18 Years – 80 Years
- Healthy volunteers
- Not accepted
Summary
The present study is designed to collect safety/tolerability data and explore the efficacy of RAD001 in advanced pulmonary neuroendocrine tumor in Chinese patients.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | RAD001 |
Timeline
- Start date
- 2010-12-01
- Primary completion
- 2014-06-01
- Completion
- 2014-06-01
- First posted
- 2011-03-29
- Last updated
- 2014-12-30
Locations
4 sites across 1 country: China
Source: ClinicalTrials.gov record NCT01324492. Inclusion in this directory is not an endorsement.